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ejection fractions (EFs) of 40% to 49% that are, by definition,
abnormal. Excluding borderline abnormal EFs from systolic heart
failure leads to a more homogeneous population wherein manage-
ment is substantially evidence-based. However, including border-
line abnormal EFs in PSF renders the terminology self-
contradictory, because systolic function is normal in diastolic heart
failure (2). Rather than imposing a definition, if the authors query
the frequency distribution of EFs is there a bimodal curve? Where
are the peaks; what are the distributions? Is there significant
overlap? What percent fall into the 40% to 49% range? Are these
patients similar to patients with systolic dysfunction; with diastolic
heart failure (EFs 50%), such that the concept of normal left
ventricular function needs to be revisited; or best considered in a
gray zone, such that they cannot be placed into either group at this
time?
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Effect of Door-to-Balloon
Time on Patient Mortality
The study by McNamara et al. (1) from the National Registry of
Myocardial Infarction (NRMI) found that door-to-balloon time
(DBT) was strongly associated with mortality in both high- and
low-risk patients and in patients presenting early or late after the
onset of symptoms. These findings differ from our analyses from a
large randomized trial and a single-center registry, both of which
found that DBT impacts mortality primarily in high-risk patients
and in those presenting early after the onset of symptoms (2,3).
Several possible explanations account for these differences.
Prolonged DBT may be confounded with other unmeasured
variables that impact mortality. First, DBT may be a surrogate for
quality of care—hospitals with long DBTs may provide subopti-
mal treatment. Data from single-center registries and randomized
trials would be less likely to have this bias. Second, NRMI data on
time from symptom onset to presentation collected from retro-
spective chart reviews may be unreliable because the time of
symptom onset is often not documented in hospital charts. This is
less of a problem in randomized trials or carefully constructed
prospective registries. Finally, and perhaps most importantly,
prolonged DBTs often reflect the underlying severity of illness,
with “sicker” patients requiring longer time for evaluation, stabi-
lization, or treatment of complications prior to percutaneous
coronary intervention (PCI) (e.g., cardiopulmonary resuscitation,
intubation, defibrillation, or insertion of temporary pacemakers or
intra-aortic balloon pumps). These confounding variables are
rarely accounted for in large registries, including NRMI.
In addition, the findings by McNamara et al. (1) that DBT
affects mortality even in patients presenting late contradict the
widely held paradigm regarding the time-sensitivity of reperfusion
therapy originally demonstrated by Reimer et al. (4) and recently
re-emphasized by Gersh et al. (5).
This issue is more than academic. We believe that an excessive
emphasis on minimizing DBT as the overriding quality-of-care
measure by hospitals, insurers, and regulators (and guidelines com-
mittees) may at times detract from optimal patient care. Rushing to
perform primary PCI before stabilizing unstable patients may lead to
laboratory complications and worse clinical outcomes. Indiscriminant
treatment with fibrinolytic therapy of ST-segment elevation myocar-
dial infarction patients presenting at noninterventional hospitals,
rather than transferring appropriate patients for primary PCI,
deprives these patients of the benefits of higher rates of reperfu-
sion, less reinfarction, less intracranial hemorrhage, and in many
cases lower mortality. A recent meta-analysis of randomized trials
with primary PCI versus fibrinolysis has shown primary PCI
reduced mortality even with treatment delays up to 2 h (6).
Decisions regarding triage of patients for primary angioplasty
should thus be based on an assessment of time and risk, and should
utilize common sense. High-risk patients presenting early after the
onset of symptoms with long delays to primary PCI are probably
best treated with fibrinolytic therapy. Most other patients are best
treated with transfer for primary PCI despite longer treatment
delays.
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